Business Update & Financial Outlook

Oncology: KEYTRUDA continues to drive strong growth • KEYTRUDA sales of $6.3B increased 21% year-over-year, driven by uptake in earlier stage cancers and continued strong global demand from metastatic indications In the U.S., growth of 21% reflects strong utilization across earlier stage cancers such as TNBC, as well as certain types of RCC and melanoma KEYTRUDA (pembrolizumab) Injection 100 mg $6.3B +21% Ex-U.S., 22% increase driven by demand in metastatic RCC and certain types of H&N cancer, as well as earlier stage cancers, including high-risk early stage TNBC and RCC $5.3B +30% $4.2B +20% Growth rates exclude the impact of foreign exchange. 2Q21 2Q22 2Q23 MERCK 11

View entire presentation